MoonLake Immunotherapeutics signs commercial supply and capacity agreements with Vetter for sonelokimab

MoonLake Immunotherapeutics

Master Commercial Supply Agreement signed May 22, 2026 with Vetter for manufacturing pre-filled application systems.
Capacity Agreement commits MoonLake to binding annual minimum and maximum quantity orders; failure may trigger compensation.
Agreements include pricing adjustment provisions based on Vetter’s cost increases and change-of-control termination rights.
Sonelokimab is MoonLake’s key product candidate; deal supports potential commercialization.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MoonLake Immunotherapeutics entered into Master Commercial Supply Agreement with Vetter Pharma International GmbH (effective 2026-05-22).

Action: entry
Agreement: supply
Counterparty: Vetter Pharma International GmbH
Effective: 2026-05-22

Exact text from the filing

On May 22, 2026, MoonLake Immunotherapeutics (the “Company”) entered into a Master Commercial Supply Agreement (the “Vetter MCSA”) with Vetter Pharma International GmbH (“Vetter”).

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

MoonLake Immunotherapeutics entered into Capacity Agreement with Vetter Pharma International GmbH (effective 2026-05-22).

Action: entry
Agreement: supply
Counterparty: Vetter Pharma International GmbH
Effective: 2026-05-22

Exact text from the filing

Also on May 22, 2026, the Company and Vetter entered into a Capacity Agreement (the “Vetter Capacity Agreement”), under which the Company is required to provide Vetter with its aggregate demand for a product for a certain period, with the annual demands for the initial term of such forecast constituting a binding capacity reservation commitment (the “MoonLake Commitment”).

View on SEC.gov

Browse all material agreements →

MoonLake Immunotherapeutics filing history →

Source: SEC EDGAR

accession 0001213900-26-063125

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.